Cook Group, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cook Group, Inc.
Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Kaia Health Publishes Study Showing Digital Physical Therapy Corrections On Par With Human Therapist
Kaia Health published a study suggesting its digital physical therapy is not inferior to seeing a physiotherapist. Digital app makers focusing on rehabilitating musculoskeletal conditions have seen significant growth during the pandemic.
IPO Edition: Caribou, AbSci and HCW launched initial public offerings, but three firms that were expected to go public during the week of 19-23 July did not, raising the question of whether investors are beginning to pull back from biopharma offerings.
- Medical Devices
- Consumables, Central Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Cook Biotech, Inc.
- Cook Medical
- Cook MyoSite
- Cook Regentec
- Medical engineering Device Institue (MED Institute)
- William A. Cook Australia Pty. Ltd